Developmental changes of sialylation of soluble beta/A4 amyloid protein precursor derivatives in human cerebrospinal fluid.
Soluble beta/A4 amyloid protein precursor derivatives (APPs) in cerebrospinal fluid from infants, children, adults and aged individuals were treated with neuraminidase. In the samples from infants, reduction of molecular weight of APPs following neuraminidase treatment was significantly less than those from adults or aged individuals. Hyposialylation of beta/A4 amyloid protein precursor in infants may be relevant to a physiological role of this molecule in the development of the nervous system.
Sodeyama
N
N
Department of Neurology, School of Medicine, Tokyo Medical and Dental University, Japan.
Saito
F
F
Saito
K
K
Miyatake
T
T
Yanagisawa
K
K
D000328:Adult; D000367:Age Factors; D000368:Aged; D000544:Alzheimer Disease / Q000134:cerebrospinal fluid; D016564:Amyloid beta-Protein Precursor / Q000134:cerebrospinal fluid* / Q000235:genetics; D000906:Antibodies; D015153:Blotting, Western; D002648:Child; D006801:Humans; D007223:Infant; D008970:Molecular Weight; D019158:N-Acetylneuraminic Acid; D009439:Neuraminidase; D012794:Sialic Acids / Q000134:cerebrospinal fluid
D016564:Amyloid beta-Protein Precursor; D000906:Antibodies; D012794:Sialic Acids; D009439:Neuraminidase; D019158:N-Acetylneuraminic Acid